VANI — Vivani Medical Inc · catalysts, narrative & risks

Vivani Medical (VANI) — Research Snapshot as of 2026-10-27

Company profile: Vivani Medical is a clinical-stage biopharmaceutical company based in Alameda, California, trading on Nasdaq under ticker VANI. It develops miniature, subdermal drug implants using its proprietary NanoPortal™ platform, targeting chronic-disease management via once- or twice-yearly drug delivery. Its lead candidate is NPM-139 (a semaglutide/GLP-1 implant for chronic weight management), with NPM-133 (semaglutide for type 2 diabetes) in the pipeline, plus the neurostimulation subsidiary Cortigent (brain-computer interface / artificial vision). [3], [22], [24]

Market snapshot: Stock ~$1.14, market cap ~$102.8M, shares outstanding ~90.2M, beta 3.30 (high volatility), short interest ~0.99% of float, insider ownership ~53.3%, institutional ~6.8%. [14], [16], [18]

---